Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-40X
- Development stage
- Preclinical
- Lead developer
- MabTics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MT-40X is an early-stage, tumor-targeting therapeutic candidate being co-developed by MabTics and Curacle for the treatment of solid cancers. Originating from MabTics's proprietary EAGLES platform, MT-40X is designed as either a T-cell engager or an antibody-drug conjugate (ADC) targeting an undisclosed tumor antigen. The program is currently in the discovery (lead generation) stage, with development being conducted intravenously under a joint research and development agreement between MabTics and Curacle.
- Other names
- MT-40xMT40xMT 40x
Beyond the preview
Go deeper on MT-40X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-40X.